Drug intelligence / Profile preview

SP-014

Development stage: Preclinical
Lead developer: Sunny Pharmtech
Modality: Small Molecules
Administration: Ophthalmic

Overview

SP-014 is a small molecule therapeutic candidate being developed by Sunny Pharmtech for the treatment of dry eye disease. The drug is formulated as a preservative-free eye drop, intended to address the symptoms and underlying causes of ocular surface dryness and irritation. As of mid-2024, the program is in the research and development (R&D) stage, representing an early-stage asset in Sunny Pharmtech's ophthalmic pipeline.

Beyond the preview

Go deeper on SP-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-014.

Explore the full profile